(3)
NEW YORK and LONDON, Jan. 13, 2021 (GLOBE NEWSWIRE) Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.
Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as
in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I-IV programs. Multiple IND s, NDA/BLA filings and/or defense and multiple successful launches.
Notes to Editors
United Oil & Gas is a high growth oil and gas company with a portfolio of low-risk, cash generative production and development assets across Egypt, UK, Italy and a high impact exploration licence in Jamaica.
Led by an experienced management team with a strong track record of growing full cycle businesses and partnered with established industry players, the Company is well positioned to deliver future growth through portfolio optimisation and targeted acquisitions.
United Oil & Gas is listed on the AIM market of the London Stock Exchange. For further information on United Oil and Gas please visit https://www.uogplc.com/
Share:
NEW YORK and LONDON, Jan. 13, 2021 (GLOBE NEWSWIRE) Tiziana Life Sciences plc (NASDAQ:TLSA) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.
Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as
in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. Multiple IND s, NDA/BLA filings and/or defense and multiple successful launches.